Search International and National Patent Collections

1. (WO2018222831) TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA

Pub. No.:    WO/2018/222831    International Application No.:    PCT/US2018/035336
Publication Date: Fri Dec 07 00:59:59 CET 2018 International Filing Date: Fri Jun 01 01:59:59 CEST 2018
IPC: A61K 31/00
A61P 35/00
C07D 213/00
C12Q 1/68
G01N 33/574
Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION
Inventors: DALEY, George Q.
JHA, Deepak K.
Title: TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
Abstract:
Described herein are methods for treating cancer. Aspects of the invention relate to administering to a subject a compound that targets a KDM4 or KDM5 family member, wherein the subject has at least one mutation in an epigenetic modifier selected from the group consisting of: EZH2, KMT2D, CREBPP, and EP300. In one embodiment, the compound is J1B04. Another aspect of the invention relates to a method of treating diffuse large B-cell lymphoma.